New appointment at Greenleaf Health
This article was originally published in Scrip
Former US FDA commissioner Dr Andrew von Eschenbach has joined the regulatory consulting firm Greenleaf Health as a senior advisor. Dr von Eschenbach, a urologic oncologist and former director of the National Cancer Institute, left the FDA on January 20th. At Greenleaf he will be reunited with Patrick Ronan, the firm's founder and president, who served as Dr von Eschenbach's chief of staff at the FDA in 2005 and 2006. Mr Ronan was vice-president of regulatory policy and external affairs at Novartis before starting his own consulting firm last year.
You may also be interested in...
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.
FDA's recommendation that COVID-19 vaccine sponsors conduct two months of median follow-up to support an emergency use authorization may not be long enough, some experts say in what can be viewed as validation for agency's position in battle with White House.
There are 18 people on the committee that will issue the first recommendations on COVID-19 vaccine development and licensure. Among the experts are a University of Michigan epidemiologist who will serve as acting chairman and seven temporary voting members, two of whom required conflict-of-interest waivers.